Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group

Antonarelli, Gabriele; Corti, Chiara; Zucali, Paolo Andrea; Perrino, Matteo; Manglaviti, Sara; Russo, Giuseppe Lo; Varano, Gianluca Maria; Salvini, P.; Curigliano, Giuseppe; Catania, Chiara; Conforti, Fabio; Pas, Tommaso De

doi:10.1016/j.ejca.2022.07.009

Cited by 10 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study adopting a continuous oral administration also confirmed that the ORR of sunitinib was better in TC (41.7% vs. 14.3%), but the disease control rate was better in TM (100% vs. 75%), indicating that the response rate might be related to the tumor invasiveness. 58 In a phase II clinical study recruiting advanced or metastatic TC, 42 patients were treated with lovatinib, 16 patients had partial response, 24 patients had stable disease, the ORR was 38%, and the disease control rate was 95%. 59 Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has also achieved good efficacy in TET.…”

Section: Targeted Therapymentioning

confidence: 99%

Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors

Zhang

Wang

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

Thymic epithelial tumors (TETs) are a relatively rare type of thoracic tumor, accounting for less than 1% of all tumors. The incidence of TETs is about 3.93/10000 in China, slightly higher than that of European and American countries. For resectable TETs, complete surgical resection is recommended. Radiotherapy or chemotherapy may be used as postoperative adjuvant treatment. Treatment for advanced, unresectable TETs consist mainly of radiotherapy and chemotherapy, but there is a lack of standard first‐ and second‐line treatment regimens. Recently, targeted therapies and immune checkpoint inhibitors have shown promising outcomes in TETs. Based on the currently available clinical evidences and the opinions of the national experts, the Thymic Oncology Group of Yangtze River Delta Lung Cancer Cooperation Group (East China LUng caNcer Group, ECLUNG; Youth Committee) established this Chinese expert consensus on the clinical diagnosis and treatment of TETs, covering the epidemiology, diagnosis, treatment, prognosis and follow‐up of TETs.

show abstract

Section: Targeted Therapymentioning

confidence: 99%

Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors

Zhang

Wang

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…Although there are no further recognized standard lines of chemotherapy, interesting results have been reported in the literature regarding the combination of capecitabine plus gemcitabine (CAP-GEM) and the tyrosine kinase inhibitor sunitinib, while imatinib can be considered for thymic carcinoma with c-KIT mutation [ 20 , 21 , 22 , 23 ]. A recent retrospective analysis from the TYME Italian collaborative group examined data from 20 patients with platinum-resistant TETs receiving continuous daily dosing (CDD) of sunitinib at a dosage of 37.5 mg [ 24 ]. The authors concluded that the CDD schedule showed similar effectiveness but a better toxicity profile as compared with intermittent dosing historical data.…”

Section: Treatmentmentioning

confidence: 99%

Current Treatment Approaches for Thymic Epithelial Tumors

Tartarone

Lerose

Lettini

et al. 2023

Life

View full text Add to dashboard Cite

Thymic epithelial tumors (TETs), including thymoma, thymic carcinoma and neuroendocrine tumors, are uncommon tumors that originate from the epithelial cells of the thymus. Nevertheless, despite their rarity, they represent the most common tumor type located in the anterior mediastinum. Therapeutic choices based on staging and histology may include surgery with or without neoadjuvant or adjuvant therapy represented by chemotherapy, radiotherapy or chemo-radiotherapy. For patients with advanced or metastatic TETs, platinum-based chemotherapy remains the standard first-line treatment; however, some new drugs and combinations are currently under evaluation. In any case, proper management of patients with TETs requires a multidisciplinary team approach to personalize care for each patient.

show abstract

“…Different trials have tested and proved the efficacy of sunitinib, an anti-angiogenic and multikinase inhibitor targeting VEGF receptors, in thymic carcinomas and thymomas refractory to first-line chemotherapy, reaching disease control in up to 91% of thymic carcinomas and 86% of thymomas. Given this evidence, sunitinib has now been introduced as a standard second-line treatment for patients with thymic carcinoma who have progressed after first-line chemotherapy ( Figure 3 ) [ 123 , 124 , 125 , 126 ]. Similarly, lenvatinib, another VEGFR/multikinase inhibitor, showed promising effects on advanced or metastatic thymic carcinomas, with presumably higher efficacy than sunitinib [ 127 ].…”

Section: Diagnostic and Therapeutic Approachesmentioning

confidence: 99%

Thymic Epithelial Tumors: An Evolving Field

Kuhn

Pescia

Mendogni

et al. 2023

Life

View full text Add to dashboard Cite

Despite their rarity, thymic epithelial tumors (TETs) have attracted much interest over the years, leading to an impressive number of histological and staging classifications. At present, TETs are divided by the WHO classification into four main subtypes: type A, type AB, and type B thymomas (subdivided into B1, B2, and B3), and thymic carcinomas, going from the more indolent to the most aggressive ones. Among many debated staging proposals, the TNM and the Masaoka–Koga staging systems have been widely accepted and used in routine practice. The four-tiered histological classification is symmetrically mirrored by the molecular subgrouping of TETs, which identifies an A-like and an AB-like cluster, with frequent GTF2I and HRAS mutations; an intermediate B-like cluster, with a T-cell signaling profile; and a carcinoma-like cluster comprising thymic carcinomas with frequent CDKN2A and TP53 alterations and a high tumor molecular burden. Molecular investigations have opened the way to tailored therapies, such as tyrosine kinase inhibitors targeting KIT, mTOR, and VEGFR, and immune-checkpoints that have been adopted as second-line systemic treatments. In this review, we discuss the crucial events that led to the current understanding of TETs, while disclosing the next steps in this intriguing field.

show abstract

Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group

Cited by 10 publications

References 21 publications

Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors

Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors

Current Treatment Approaches for Thymic Epithelial Tumors

Thymic Epithelial Tumors: An Evolving Field

Contact Info

Product

Resources

About